1. Jubilant Therapeutics Inc. Reports Development of Orally Available and Brain Penetrant Small Molecule Inhibitors of PD-L1 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Jubilant Therapeutics Inc. recently announced data to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The data report is on the pharmacokinetic and in vitro and in vivo anti-cancer properties of JBI-2174, the Company’s lead oral, brain penetrant PD-L1 inhibitor, which is in IND-enabling studies for the treatment for solid tumors. For more information please click here.
2. Jubilant HollisterStier announces CAD 100 Mn expansion of its CMO manufacturing facility at Montreal, Canada and Government of Quebec funding of CAD 25 Mn through a loan
Jubilant Pharmova Limited’s wholly owned subsidiary Jubilant Pharma Limited, through one of its wholly owned subsidiaries, Jubilant HollisterStier General Partnership, (JHS), announced recently that the Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million, which includes a forgivable portion of CAD 6.3 million to fund the CAD 100 Mn capacity expansion at the CMO Montreal facility. For more information please click here.